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Abstract
Rationale: Biomarkers for survival in amyotrophic lateral sclerosis
(ALS) would facilitate the development of novel drugs. Although
respiratory muscle weakness is a known predictor of poor prognosis,
a comprehensive comparison of different tests is lacking.
Objectives: To compare the predictive power of invasive and
noninvasive respiratory muscle strength assessments for survival or
ventilator-free survival, up to 3 years.
Methods: From a previously published report respiratory muscle
strength measurements were available for 78 patients with ALS. Time to
deathand/orventilationwereascertained.Receiveroperatingcharacteristic
analysis was used to determine the cutoff point of each parameter.
Measurements and Main Results: Each respiratory muscle
strength assessment individually achieved statistical signiﬁcance for
prediction of survival or ventilator-free survival. In multivariate
analysis sniff trans-diaphragmatic and esophageal pressure, twitch
trans-diaphragmatic pressure (Tw Pdi), age, and maximal static
expiratory mouth pressure were signiﬁcant predictors of ventilation-
free survival and Tw Pdi and maximal static expiratory mouth
pressure for absolute survival. Although all measures had good
speciﬁcity, there were differing sensitivities. All cutoff points for the
VC were greater than 80% of normal, except for prediction of
3-month outcomes. Sequential data showed a linear decline for direct
measures of respiratorymuscle strength, whereas VC showed little to
no decline until 12 months before death/ventilation.
Conclusions: The most powerful biomarker for mortality
stratiﬁcation was Tw Pdi, but the predictive power of sniff nasal
inspiratory pressure was also excellent. A VC within normal range
suggested a good prognosis at 3 months but was of little other value.
Keywords: amyotrophic lateral sclerosis; survival; diaphragm;
maximal inspiratory pressure; sniff nasal inspiratory pressure
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Amyotrophic lateral sclerosis (ALS) is a
progressive and devastating neurologic
condition characterized by progressive
muscle weakness. Although riluzole is
licensed for ALS treatment (1), the beneﬁts
in clinical practice have proved modest and
new drugs are urgently required. ALS-
related respiratory muscle weakness is
relatively uncommon at presentation, but
hypercapnic respiratory failure caused by
muscle weakness is common in established
ALS. Although noninvasive ventilation
(NIV) is an effective therapy, especially for
patients with nonbulbar disease (2, 3), it
comes with a poorer prognosis and the
inconvenience of wearing a ventilator
apparatus; therefore, it may be considered
a “hard” adverse endpoint.
For most conditions, including ALS,
trials powered to detect improvements
in survival are expensive. This may delay
the evaluation and introduction of new
drugs or technologies (e.g., diaphragm
pacing). Therefore biomarkers, either as
a surrogate outcome measure or as a
stratiﬁcation tool, would be useful to
enrich the study population for those at
high risk of meeting the endpoint. In ALS,
mortality or the need for ventilator support
are objective endpoints that additionally
have obvious validity to patients,
regulators, and payers.
Several studies have identiﬁed
respiratory muscle weakness, measured
directly or as VC, as a predictor of daytime
respiratory failure (4) or death (5–7).
Respiratory muscle strength could therefore
be a valuable biomarker. However, there are
some gaps in the literature diminishing the
value of current data. First, the literature
disproportionately depends on VC as a
measure of respiratory muscle strength.
Although VC has some advantages (e.g.,
widespread availability), the relationship
of directly measured respiratory muscle
strength with VC is, as expected from the
pulmonary pressure volume curve (8), not
linear (9). Therefore it is unknown whether
VC is responsive to disease progression
throughout the entire disease course.
Second, no large-scale study has compared
the prognostic power of direct
measurement of diaphragm function as
trans-diaphragmatic pressure with
noninvasive measures. Third, the
prognostic value of nonvolitional measures
of respiratory muscle function have not
been evaluated, with the exception of Pinto
and coworkers (10), who undertook
phrenic nerve stimulation. However, they
used an electrical technique, which can be
unreliable even in experienced hands (11),
and used the compound muscle action
potential as outcome measure rather than a
measure of force. Lastly, most studies are
limited by the lack of sequential data and a
short follow-up, leaving a proportion of the
participants alive, thus diminishing
statistical power.
Between 1996 and 2000, we studied (4)
a large group of patients with ALS (n = 81)
using invasive and noninvasive measures of
respiratory muscle function (12); however,
our prior publication presented only cross-
sectional data and explored the relationship
between respiratory muscle strength and
daytime and nocturnal hypercapnia. In the
current analysis, conducted between 2014
and 2015, the value of these measures for
the prediction of death or initiation of NIV
was assessed.
Methods
Participants
The present study used respiratory muscle
function data from a previously published
ALS patient cohort, containing 81 patients
(16 females) studied between 1996 and 2000
(4). Entry into the study was not dependent
on the presence or absence of respiratory
symptoms. The date of death was
ascertained in 2014, using hospital and
central NHS records. Treatment with NIV
was obtained from the clinical records,
where available.
Participants were recruited from the
King’s MND Care and Research Centre,
where a diagnosis of ALS was conﬁrmed by
a consultant with a special interest in ALS
and classiﬁed as El Escorial “possible,
probable, or deﬁnite” (13). The study was
approved by the Kings College Hospital
ethics committee and all patients provided
written informed consent.
Measurements
At the time of assessment, none of the
patients had received ventilatory support,
although several were subsequently
treated with noninvasive positive-
pressure ventilation. The respiratory
muscle strength measurement protocol has
been described previously (4). The
following parameters were included: VC,
maximal static inspiratory and expiratory
mouth pressures (MIP and MEP,
respectively), maximal sniff nasal
inspiratory pressure (SNIP), maximal
sniff esophageal (Sn Pes) and trans-
diaphragmatic pressures (Sn Pdi),
unpotentiated twitch trans-diaphragmatic
pressure (Tw Pdi) using cervical magnetic
stimulation (14, 15), maximal cough
gastric pressure (Cough Pga) (16), and
the unpotentiated twitch abdominal
pressure elicited by magnetic stimulation
of the 10th thoracic intervertebral space
(Tw T10) (17).
At a Glance Commentary
Scientiﬁc Knowledge on the
Subject: Although respiratory muscle
weakness is known to be associated
with a poor prognosis in amyotrophic
lateral sclerosis (ALS), there are no
comprehensive data that compare the
prognostic power of different tests of
inspiratory and expiratory muscle
function at different time intervals.
However, such data would facilitate
enrichment of phase IIa studies of
novel agents aiming to reduce
mortality in ALS.
What This Study Adds to the
Field: In a cohort of patients with ALS
followed until 100% mortality
occurred, invasive and noninvasive
tests of respiratory muscle strength
were performed, allowing the
predictive power for death or
noninvasive ventilation of each test at
time intervals up to 3 years to be
assessed and for relevant cutoff points
to be obtained. The best performing
tests were sniff and twitch trans-
diaphragmatic pressure, but maximal
sniff nasal inspiratory pressure also had
excellent predictive power; sniff nasal
inspiratory pressure values of 52, 71,
85, and 88 cm H2O displayed greater
than or equal to 95% sensitivity for
predicting death or noninvasive
ventilation use at 6, 12, 24, and
36 months, respectively. Although
vital capacity also had good predictive
power, the cutoff point indicating a
poor prognosis was within the normal
range (i.e., .80% predicted) for all
time intervals beyond 3 months,
making this a less useful stratiﬁcation
variable for most studies.
ORIGINAL ARTICLE
Polkey, Lyall, Yang, et al.: Respiratory Muscle Strength and Survival in ALS 87
Statistical Analyses
A stepwise selection method using Cox
regression was performed to determine the
relationship between each variable and
both survival and ventilation-free survival.
The following variables were included in
the stepwise regression analysis: Tw Pdi
(cm H2O), Sn Pdi (cm H2O), Sn Pes (cm
H2O), SNIP (cm H2O), SNIP (percent-
predicted), VC (percent-predicted), MIP
(cm H2O), MIP (percent-predicted), MEP
(cm H2O), MEP (percent-predicted),
Cough Pga (cm H2O), age, and sex. In
selection steps, the score tests for each
variate not in the model are performed,
and are used to determine which variate
should be added to or removed from the
model. The stepwise selection signiﬁcance
levels for entering and removing were
0.2 and 0.1, respectively. The selection
process was repeated until no further
effect could be added to the model or
if the current model is identical to a
previously visited model. Sensitivity and
speciﬁcity analyses, for the prediction of
survival and ventilation-free survival,
were performed for each parameter at
3-month intervals until 18 months and
thereafter at 6-month intervals until the
third year. Furthermore, the relationship
of the strongest predictors from the
multivariate analysis model with
noninvasive measures of respiratory
muscle strength was investigated.
The values derived from the receiver
operating characteristic (ROC) plot,
offering the greatest sensitivity and
sensitivity (i.e., ratio of sensitivity/[1-speciﬁcity],
as a function of time), were plotted for each
parameter. Kaplan-Meier survival analyses
were performed, correlating death or the date of
initiation of NIV for each parameter, with three
groups based on normal values for each test: (1)
greater than or equal to 80% predicted
(i.e., within the normal range), (2) 45% to less
than 80% predicted, and (3) less than 45%
predicted.
For patients in whom multiple
measures were available, graphical plots
were used to determine the trajectory of
each parameter before death.
Results
After review of the source (paper) data (4)
and the date of death, 78 patients (17
females) were included. Only 21.8% of the
sample were women; this was not the result
of any deliberate recruitment bias and
compares with an overall clinical
population with a male/female ratio of
approximately 3:2.
Riluzole was taken by the majority of
patients. The long time-interval between
respiratory function measurement
(1996–2000) and survival analysis
(2014–2015) unfortunately ensured a 100%
mortality rate in our cohort. The patients
survived a mean 744 days from the date of
inclusion in the previously published
cohort (4). NIV was offered to patients
managed by our institution, but this was
not universal practice in the United
Kingdom at the time. Therefore, NIV was
not offered to some participants. In
addition, because of the wide geographic
referral base of the King’s MND Care and
Research Centre, NIV data could not be
obtained for some (n = 9) cases.
The mean (SD) age of the included
patients was 61 (8.7) years and they had a
mean (SD) ALS functional rating score of 28
(6), a mean (SD) Norris limb score of 41
(12.9) out of 63, and a mean Norris bulbar
score of 34 (8.5) out of 39 (Table 1). As
expected and as shown in Table 1, a
range of respiratory muscle weakness
was observed in the patient population;
inherent to the condition not all patients
had the stamina to complete all the tests
and where so we opted to prioritize
respiratory muscle tests. Numbers for the
datasets available for each parameter are
also given in Table 1.
Predictive Value of Respiratory
Muscle Strength Tests for Death and
NIV
A stepwise regression analysis was
performed in all patients who had complete
data (n = 57) for all tested variables (Tw
Pdi, Sn Pdi, Sn Poes, SNIP, VC, MIP, MEP,
Cough Pga, age, and sex).
In the stepwise regression analysis for
ventilation-free survival (Table 2), all
respiratory muscle strength assessments
achieved statistical signiﬁcance (P, 0.05)
in their individual test scores, whereas no
signiﬁcance was observed for sex (P = 0.83)
or age (P = 0.81). Sn Pdi and Tw Pdi had
the highest values in the individual test
scores, whereas the lowest values were
registered for age and sex. In the ﬁnal
multivariate analysis model for ventilation-
free survival, ﬁve variables retained
signiﬁcance: (1) age (P = 0.0027), (2) Tw
Pdi (P, 0.0001), (3) Sn Pdi (P = 0.0025),
(4) Sn Poes (P = 0.0275), and (5) MEP %
predicted (P = 0.0544) (Table 3).
In the stepwise regression analysis for
absolute survival (Table 2), each respiratory
muscle strength assessment achieved
statistical signiﬁcance (P, 0.05) in their
individual score tests, whereas no
signiﬁcance was observed for sex (P = 0.68)
or age (P = 0.11). The highest values in the
individual score tests were observed for Sn
Pdi and Tw Pdi, whereas the lowest values
were registered for sex and age. In the ﬁnal
analysis model for absolute survival, two
variables retained signiﬁcance: Tw Pdi
(P = 0.0018) and MEP (P = 0.0073)
(Table 3).
The sensitivity and speciﬁcity of the key
noninvasive (VC, SNIP,MIP, andMEP) and
invasive (Tw Pdi and Sn Pdi) respiratory
muscle strength measures to predict death
or the use of NIV as a function of time
before that event and at time points up to
3 years are shown in Tables 4 and 5, and
Table E2 in the online supplement for the
MEP. The cutoff values and area under the
curve, identiﬁed from the ROC analysis, as
a function of time before that event and at
time points up to 3 years are shown in
Figures 1 and E1, respectively. ROC
analyses showed area under the curve
greater than 0.8 at most time points for all
tests, but the numerical range of cutoff
points varied. It should be noted that
although all measures had good to excellent
speciﬁcity, there were widely differing
sensitivities for the prediction of death or
ventilator use. The VC value that gave the
best cutoff point was higher than 80%
predicted at all time points, except for
outcome prediction at 3 months.
Figure 2 shows the Kaplan-Meier
survival curves for the three principle
techniques (VC, SNIP, and MIP) used for
noninvasive assessment of inspiratory
muscle strength. For each parameter, the
participants were categorized into the
following subgroups: greater than or equal
to 80% predicted (i.e., within the normal
range), 45% to less than 80% predicted, and
less than 45% predicted. Although, a result
within the normal range was associated
with the longest survival for all three
noninvasive inspiratory muscle strength
parameters, VC discriminated less between
moderate and severe weakness compared
with SNIP and MEP.
Sequential measures of respiratory
muscle strength were obtained for only
25 participants on 2–11 occasions either
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because it was impractical for most of the
visits or the patient declined to participate.
Figure 3 shows the serial behavior of
respiratory muscle strength parameters in
those 25 patients in whom serial measures
were available. The VC declined slowly
until 12 months before death, followed by a
rapid decline until death. In contrast, a
more linear pattern was observed for direct
measures of respiratory muscle strength,
including SNIP (% predicted), Sniff Pdi
(cm H2O), Twi pdi (cm H2O), MIP
(% predicted), and MEP (% predicted).
A correlation of Tw Pdi with Sn Pdi and
with noninvasive measures of respiratory
muscle strength, including MIP, SNIP, and
VC, was observed (Figure 4).
Discussion
Formost conditions, trials powered to detect
improvements in survival are expensive.
This may delay the evaluation and
introduction of novel drugs or technologies
aiming to reduce mortality. Therefore
biomarkers, either as a surrogate outcome or
as a stratiﬁcation tool, would be useful to
enrich trials for those at high risk of meeting
the study endpoint.
Critique of the Method
Each respiratory muscle strength
assessment individually achieved statistical
signiﬁcance for prediction of death or
ventilator-free survival. These ﬁndings are
Table 1. Demographic Data of Participants
Score Indicating
Normal Function n (of 78) Mean SD Median Q1, Q3
Demographics
Age, yr — 78 61 8.7 61 55, 66
Sex, male/female — 78 61/17 —
ALS FRS 40 55 28 5.6 29 23, 32
Norris limb 63 58 41 12.9 41.5 36, 49
Norris bulbar 39 58 34 8.5 35 30, 39
MRC UL 60 48 53 7.5 55 46.5, 59
MRC LL 40 48 33 8.7 37 28.5, 40
MRC neck 10 48 9 1.2 10 8.5, 10
Respiratory muscle strength
Tw Pdi, cm H2O .18 77 15.0 12.7 9.9 5.7, 23.9
Sn Pdi, cm H2O .70 77 57.6 43.3 47 19.7, 88.9
Sn Pes, cm H2O .60 77 54.0 32.3 45 31.9, 71
MIP, cm H2O — 75 36.2 26.0 28 18, 47
MIP, % predicted — 75 43.6 29.2 35 21.2, 63
MEP, cm H2O — 75 48.6 30.1 39 28, 67
MEP, % predicted — 75 40.7 22.2 41.35 22.2, 58
VC, % predicted — 74 71.5 27.6 68.5 50, 97.8
SNIP, cm H2O .60 62 51.0 31.7 44 27.7, 66
SNIP, % predicted — 62 52.8 30.8 44.85 27.9, 76.75
Cough Pga, cm H2O — 75 91.8 61.0 83 42.25, 121.8
Tw T10, cm H2O — 70 15.9 14.0 12 5.7, 22
Definition of abbreviations: ALS FRS = Amyotrophic Lateral Sclerosis Functional Rating Scale; Cough Pga = cough gastric pressure; LL = lower limb;
MEP =maximal static expiratory mouth pressure; MIP =maximal static inspiratory mouth pressure; MRC =Medical Research Council; Q1 = quartile 1;
Q3 = quartile 3; SNIP = sniff nasal inspiratory pressure; Sn Pdi = sniff trans-diaphragmatic pressure; Sn Pes = sniff esophageal pressure; Tw Pdi = twitch
trans-diaphragmatic pressure; Tw T10 = twitch abdominal pressure elicited by magnetic stimulation of the 10th thoracic intervertebral space;
UL = upper limb.
Three individuals scored zero for some of the respiratory muscle strength assessments because of an inability to perform the maneuver.
Table 2. Stepwise Regression for Ventilation-Free and Absolute Survival: Individual
Score Test Results
Ventilation-Free Survival Absolute Survival
Chi-Square P Value Chi-Square P Value
Age, yr 0.0556 0.8136 2.5544 0.1100
Sex 0.0458 0.8305 0.1746 0.6761
Tw Pdi, cm H2O 47.9799 ,0.0001 22.3576 ,0.0001
Sn Pdi, cm H2O 54.3358 ,0.0001 21.3279 ,0.0001
Sn Pes, cm H2O 29.6091 ,0.0001 20.0359 ,0.0001
SNIP, cm H2O 30.1857 ,0.0001 19.7347 ,0.0001
SNIP, % predicted 34.5232 ,0.0001 20.1526 ,0.0001
VC, % predicted 32.6306 ,0.0001 16.8896 ,0.0001
MIP, cm H2O 21.9363 ,0.0001 15.1205 0.0001
MIP, % predicted 24.0194 ,0.0001 14.3513 0.0002
Cough Pga, cm H2O 15.4459 ,0.0001 16.6363 ,0.0001
MEP, cm H2O 22.6263 ,0.0001 19.5375 ,0.0001
MEP, % predicted 30.7708 ,0.0001 19.0626 ,0.0001
Definition of abbreviations: Cough Pga = cough gastric pressure; MEP =maximal static expiratory
mouth pressure; MIP =maximal static inspiratory mouth pressure; SNIP = sniff nasal inspiratory
pressure; Sn Pdi = sniff trans-diaphragmatic pressure; Sn Pes = sniff esophageal pressure;
Tw Pdi = twitch trans-diaphragmatic pressure.
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in line with previous studies, reporting that
respiratory muscle strength measures are
strong predictors of death or the need to
use NIV. Our study did not evaluate all
tests of respiratory muscle function or
questionnaires, such as the SINQ-5 (18); in
particular supine VC has been identiﬁed as
a sensitive marker of isolated diaphragm
dysfunction in ALS (19). This test is
attractive in the sense that spirometry is
widely available but we caution that many
patients with ALS cannot easily transfer onto
a testing couch especially as the condition
progresses, and its prognostic value remains
unknown. Other techniques of reported value
for assessment of respiratory muscle function
in ALS include measurement of compound
muscle action potential elicited by phrenic
nerve stimulation (10, 20), but because this
was not measured in the current study we
are unable to comment on its value in
comparison with measurement of force as Pdi.
We also acknowledge that our analysis
is strictly conﬁned to indices of respiratory
muscle function. Thus, we have deliberately
not sought to conﬁrm whether a bulbar
presentation is associated with a poor
prognosis, which has been explored in larger
studies. Similarly nocturnal hypoventilation,
which is known to be associated with a poor
prognosis, was not explored in this analysis,
at least in part because most authorities now
consider this to be an indication for NIV.
Finally, we are aware that sequential
measures, particularly when used in
conjunction with sophisticated modeling
techniques as described by Carreiro and
coworkers (21), may offer an alternative
predictive strategy. However, particularly
for the purposes of recruiting to clinical
trials, or counseling patients, it is often
preferable to base a decision on a single
measurement.
The current cohort is not sufﬁciently
powerful to dissect factors predictive of
death once NIV has been established. Even if
it had been, it could not have accommodated
other aspects of ventilator support that are
culturally inﬂuenced (22), such as the use
of 24-hour tracheostomy ventilation
(T-IPPV). It is anecdotally accepted that
patients with ALS receiving T-IPPV and
enteral feeding live longer and may die for
reasons other than ALS (23);
unsurprisingly, the overall burden of
disease involvement may be predictive in
T-IPPV users (24).
Although the cohort is, to our
knowledge, the largest ALS cohort to have
had invasive measures of respiratory muscle
strength, only limited serial noninvasive
respiratory muscle strength data were
available.
The choice of death or NIV use as
endpoint requires defense, especially
because the patients were studied when
NIV was being introduced as a therapeutic
option for ALS in the United Kingdom.
Although all patients at the King’s Centre
were considered for NIV as appropriate,
this may not have applied to other
referring centers. This issue was conﬁrmed
Table 3. Stepwise Regression for Ventilation-Free and Absolute Survival: Final Multivariate Analysis Model of Maximum Likelihood
Estimates
Parameter Parameter Estimate Standard Error Chi-Square P Value Hazard Ratio 95% CI of Hazard Ratio
Ventilation-free survival
Age, yr 20.06332 0.02112 8.9861 0.0027 0.939 0.901–0.978
Tw Pdi, cm H2O 20.13279 0.03104 18.3039 ,0.0001 0.876 0.824–0.931
Sn Pdi, cm H2O 20.03014 0.00996 9.1576 0.0025 0.970 0.952–0.989
Sn Pes, cm H2O 0.02091 0.00949 4.8578 0.0275 1.021 1.002–1.040
MEP, % predicted 20.02138 0.01111 3.7003 0.0544 0.979 0.958–1.000
Absolute survival
Tw Pdi, cm H2O 20.03754 0.01201 9.7724 0.0018 0.963 0.941–0.986
MEP, cm H2O 20.01529 0.00570 7.1953 0.0073 0.985 0.974–0.996
Definition of abbreviations: CI = confidence interval; MEP =maximal static expiratory mouth pressure; Sn Pdi = sniff trans-diaphragmatic pressure; Sn
Pes = sniff esophageal pressure; Tw Pdi = twitch trans-diaphragmatic pressure.
Table 4. Receiver Operating Characteristic Analysis for Key Respiratory Muscle Strength Parameters up to 3 Years of Follow-up for
Ventilation-Free Survival: Noninvasive Respiratory Muscle Strength Parameters
Projected
Time (mo)
Vital Capacity (% Predicted)
Sniff Nasal Inspiratory Pressure
(% Predicted)
Maximal Static Inspiratory Mouth
Pressure (% Predicted)
Cutoff AUC Sensitivity Speciﬁcity Cutoff AUC Sensitivity Speciﬁcity Cutoff AUC Sensitivity Speciﬁcity
3 78 0.837 0.62 0.96 49 0.877 0.61 0.95 51 0.731 0.46 0.96
6 81 0.894 0.61 0.97 52 0.859 0.55 0.95 54 0.796 0.49 0.97
9 85 0.906 0.63 0.97 71 0.865 0.50 0.96 64 0.813 0.44 0.97
12 88 0.892 0.61 0.97 71 0.847 0.53 0.96 64 0.822 0.46 0.97
15 105 0.848 0.37 0.98 82 0.846 0.48 0.97 83 0.807 0.27 0.98
18 105 0.868 0.37 0.96 82 0.845 0.52 0.97 83 0.844 0.30 0.98
24 106 0.854 0.41 0.98 85 0.865 0.55 0.98 84 0.849 0.32 0.98
36 111 0.883 0.46 0.98 88 0.981 0.83 0.98 93 0.909 0.31 0.98
Definition of abbreviation: AUC = area under the curve.
Data for the maximal static expiratory mouth pressure are shown in Table E2.
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by a pooled analysis of 2,477 patients with
ALS participating in three (negative)
therapeutic trials reported between 2004
and 2006 (25), a similar period to the time
at which the respiratory muscle strength
measurements were made in the current
study. Unsurprisingly, variation in
ventilation practice was reported between
countries and at different institutions
within the same country, with ventilator
interventions ranging from 0 to 23.1%.
Because of this variation, a larger sample
size was required for the study of
composite endpoints compared with death
alone. However, the practical arguments in
favor of the composite endpoint of death
or ventilation from a drug development
perspective are ﬁrst that ventilation itself
represents a considerable healthcare
burden and second that, because
ventilation itself increases longevity (2),
the use of NIV might obscure a true
treatment effect of a novel therapeutic
agent.
Signiﬁcance of the Findings
Although respiratory muscle weakness is
known as a poor prognostic feature in
ALS (4–7) and other neuromuscular
disorders, such as the muscular
dystrophies or Pompe disease, there are
no comprehensive data that compare the
prognostic power of different tests of
inspiratory and expiratory muscle function
at different time intervals in any condition.
Therefore, the current study assessed the
value of noninvasive and invasive
respiratory muscle strength assessments, at
different time points up to 3 years, for the
prediction of death or the initiation of NIV
in a large cohort of patients with ALS
(n = 78) (10, 19–21).
Sn Pdi and Twi Pdi were the best
performing tests for prediction of
ventilator-free survival, but SNIP also had
excellent predictive power. Although VC
also had good predictive power for
ventilation-free survival, the cutoff value
indicating a poor prognosis was within the
normal range (i.e., .80% predicted) for all
time intervals beyond 3 months, making
this a less useful stratiﬁcation variable for
most studies. In addition, in a longitudinal
subset of our cohort the inferiority of VC
for enrichment against an endpoint of
ventilator-free survival was observed. This
is in line with ﬁndings from a pooled
analysis (in 2,477 patients with ALS)
reporting that relatively high VC values
may be observed close to a clinical
meaningful event (e.g., tracheostomy)
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Figure 1. Cutoff values of the respiratory muscle strength parameters with greatest sensitivity for
prediction of time to death or noninvasive ventilation. Graphical analysis showing the cutoff point
identified from the receiver operating characteristic analysis for the prediction of death or noninvasive
ventilation for the key respiratory muscle strength parameters as a function of time before that event.
MEP =maximal static expiratory mouth pressure; MIP =maximal static inspiratory mouth pressure;
SNIP = sniff nasal inspiratory pressure; Sn Pdi = sniff trans-diaphragmatic pressure; Tw Pdi = twitch
trans-diaphragmatic pressure.
Table 5. Receiver Operating Characteristic Analysis for Key Respiratory Muscle Strength Parameters up to 3 Years of Follow-up for
Ventilation-Free Survival: Invasive Respiratory Muscle Strength Parameters
Twitch Trans-diaphragmatic Pressure (cm H2O) Sniff Trans-diaphragmatic Pressure (cm H2O)
Projected
Time (mo) Cutoff AUC Sensitivity Speciﬁcity Cutoff AUC Sensitivity Speciﬁcity
3 9.8 0.913 0.78 0.96 47.1 0.926 0.74 0.96
6 17.0 0.919 0.60 0.97 47.1 0.951 0.82 0.97
9 17.0 0.962 0.69 0.97 55.0 0.976 0.85 0.97
12 18.6 0.943 0.70 0.98 77.2 0.963 0.65 0.98
15 26.1 0.943 0.47 0.98 89.0 0.950 0.60 0.98
18 26.1 0.938 0.52 0.98 89.0 0.952 0.67 0.98
24 28.4 0.922 0.45 0.98 103.0 0.933 0.59 0.98
36 28.4 0.958 0.77 0.98 108.5 0.978 0.85 0.98
Definition of abbreviation: AUC = area under the curve.
Data for the maximal static expiratory mouth pressure are shown in Table E2.
ORIGINAL ARTICLE
Polkey, Lyall, Yang, et al.: Respiratory Muscle Strength and Survival in ALS 91
(25). In that study, VC measurements were
available for 50 patients with ALS
requiring tracheostomy within 30 days of
the need for tracheostomy, and were 50%
or more of the predicted value in 11
patients, 60% or more of the predicted
value in seven patients, and 70% or more
of the predicted value in ﬁve patients.
Combined, these data suggest that VC is a
poor tool for assessing change until the
period immediately before death, in
contrast to Sn Pdi, Twi Pdi, and SNIP, for
which linear declines were observed in the
longitudinal cohort.
In the multivariate analysis for absolute
survival, Tw Pdi andMEP reached statistical
signiﬁcance. This conﬁrms for the ﬁrst time
a modest, but measurable impact of
expiratory muscle function on survival in
ALS. The predictive effect of MEP was
substantially weaker than the predictive
value of inspiratory muscle strength
assessments, but was retained in
multivariate analysis, and is therefore not
likely to be an epiphenomenon. It has been
previously reported that a profound
expiratory muscle weakness is associated
with the inability to generate transient
supramaximal ﬂow during a cough (26),
which has been hypothesized to reduce
defense against respiratory tract infection
and aspiration. Impaired survival has been
reported after NIV in those with mucous
accumulation (27); this perhaps points to
the inability to satisfactorily expectorate
mucous. The attenuation of the effect,
considering ventilator free-survival, was
likely caused by the beneﬁts of NIV in
reducing the impact of chest infection both
by improving blood gases but also by
preventing basal atelectasis. This
observation strengthens the case for further
study of devices that facilitate expectoration
of sputum (28, 29).
The Tw Pdi may be considered a gold
standard, because it is independent of
patient motivation or tester aptitude (14).
Our data conﬁrm the expected relationship
between volitional and noninvasive tests of
inspiratory muscle function and the Tw
Pdi. Although Tw Pdi and Sn Pdi may be
considered direct measures of diaphragm
strength, Sn Poes and SNIP reﬂect overall
inspiratory muscle strength; while the
diaphragm does constitute the majority of
inspiratory muscle function in normal
humans it is clear that Sn Poes and Sn Pdi
are not therefore measuring exactly the
same quantity. In that context Table 3 is of
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Figure 2. Kaplan-Meier analysis (for the composite endpoint of death or noninvasive ventilation use)
for the (A) VC, (B) sniff nasal inspiratory pressure, and (C) maximal static inspiratory mouth pressure.
The participants were categorized into three subgroups: greater than or equal to 80% predicted
(i.e., within the normal range), 45 to less than 80% predicted, and less than 45% predicted. The
P values of log-rank tests of equality over subgroups are all less than or equal to 0.0001.
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Figure 3. Longitudinal respiratory muscle strength data in a subset of patients for whom sequential measures were available (n = 25) for the (A) VC, (B)
sniff nasal inspiratory pressure (SNIP), (C) twitch trans-diaphragmatic pressure (Twi Pdi), (D) sniff trans-diaphragmatic pressure (Sniff Pdi), (E) maximal
static inspiratory mouth pressure (MIP), (F) maximal static expiratory mouth pressure (MEP), and (G) gastric pressure during maximal cough (Cough
Pga). Each series of dots represents the trajectory of this parameter for an individual patient. NIV = noninvasive ventilation.
ORIGINAL ARTICLE
Polkey, Lyall, Yang, et al.: Respiratory Muscle Strength and Survival in ALS 93
interest because it is noted that although
much the strongest association with
ventilation-free survival was achieved by
Tw Pdi, the associations with Sn Pdi and Sn
Poes were of opposite polarity so that
whereas in univariate analysis a reduced Sn
Poes was associated with reduced survival,
in multivariate analysis an increased Sn
Poes was statistically associated with a
slightly increased risk of death or
ventilation. We suspect this paradox
occurs because disease impact on the
nondiaphragmatic muscles (which is what
Sn Poes captures once Pdi has been
stratiﬁed for during the process of
multivariate analysis) is a marker of wider
regional involvement.
In conclusion, the value of respiratory
muscle strength as a biomarker is conﬁrmed
by the current analysis. By providing
detailed sensitivity and speciﬁcity
predictions, the present data can be used to
permit smaller sample sizes in future ALS
trials and thus to permit a more rapid
sorting of treatments into those with beneﬁt
and those without. Although VC has a good
sensitivity, the cutoff points identiﬁed by
ROC analysis were largely within the normal
range and our longitudinal data conﬁrmed
that change in VC was of small amplitude
until close to death or the need for NIV. Our
data suggest that direct measurement of
respiratory muscle strength may be a more
useful biomarker. n
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